NeuroPace completes enrollment in RNS System IDE study

NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study of the RNS System for the treatment of Lennox-Gastaut Syndrome, or LGS, a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.